首页> 外文期刊>Toxicology in vitro: an international journal published in association with BIBRA >Cytotoxicity of carteolol to human corneal epithelial cells by inducing apoptosis via triggering the Bcl-2 family protein-mediated mitochondrial pro-apoptotic pathway
【24h】

Cytotoxicity of carteolol to human corneal epithelial cells by inducing apoptosis via triggering the Bcl-2 family protein-mediated mitochondrial pro-apoptotic pathway

机译:卡特洛尔通过触发Bcl-2家族蛋白介导的线粒体促凋亡途径诱导细胞凋亡,从而对人角膜上皮细胞产生细胞毒性

获取原文
获取原文并翻译 | 示例
       

摘要

Carteolol is a frequently used nonselective p-adrenoceptor antagonist for glaucoma and ocular hypertension treatment, and its repeated/prolonged usage might be cytotoxic to the cornea, especially the outmost human corneal epithelium (HCEP). The aim of the present study was to characterize the cytotoxicity of carteolol to HCEP and its underlying cellular and molecular mechanisms using an in vitro model of HCEP cells. After HCEP cells were treated with carteolol at concentrations varying from 2% to 0.015625%, the cytotoxicity, apoptosis-inducing effect and-pro-apoptotic pathway was investigated, respectively. Our results showed that carteolol at concentrations above 0.03125% induced time- and dose-dependent growth retardation, cytopathic morphological changes and viability decline of HCEP cells. Moreover, carteolol induced G(1) phase arrest, plasma membrane permeability elevation, phosphatidylserine externalization, DNA fragmentation, and apoptotic body formation of HCEP cells. Furthermore, carteolol also induced activation of caspase-9 and -3, disruption of mitochondrial transmembrane potential, up-regulation the cytoplasmic amount of cytochrome c and apoptosis-inducing factor, and up-regulation of pro-apoptotic Bax and Bad, down-regulation of anti-apoptotic Bcl-2 and Bcl-xL. In conclusion, carteolol above 1/64 of its clinical therapeutic dosage has a time- and dose-dependent cytotoxicity to HCEP cells, which is achieved by inducing apoptosis via triggering Bcl-2 family protein-mediated mitochondrial pro-apoptotic pathway. (C) 2016 Elsevier Ltd. All rights reserved.
机译:卡特洛尔是青光眼和高眼压症治疗中经常使用的非选择性p-肾上腺素受体拮抗剂,其反复/长期使用可能对角膜,尤其是最远的人类角膜上皮(HCEP)具有细胞毒性。本研究的目的是使用HCEP细胞体外模型表征卡替洛尔对HCEP的细胞毒性及其潜在的细胞和分子机制。用浓度为2%至0.015625%的卡替洛尔处理HCEP细胞后,分别研究了其细胞毒性,细胞凋亡诱导作用和促凋亡途径。我们的结果表明,浓度高于0.03125%的卡替洛尔可诱导HCEP细胞的时间依赖性和剂量依赖性生长迟缓,细胞病变形态变化和活力降低。此外,卡替洛尔诱导HCEP细胞的G(1)相停滞,质膜通透性升高,磷脂酰丝氨酸外化,DNA片段化和凋亡小体形成。此外,Carteolol还诱导caspase-9和-3的激活,线粒体跨膜电位的破坏,细胞色素c的细胞质量和凋亡诱导因子的上调以及促凋亡Bax和Bad的上调,下调抗凋亡的Bcl-2和Bcl-xL。总之,高于其临床治疗剂量1/64的卡替洛尔对HCEP细胞具有时间和剂量依赖性的细胞毒性,这是通过触发Bcl-2家族蛋白介导的线粒体促凋亡途径诱导细胞凋亡来实现的。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号